292
Views
8
CrossRef citations to date
0
Altmetric
Oncology

Burden of advanced breast cancer for patients and caregivers in Europe: comparison of two treatment forms of vinorelbine, oral and intravenous

, , , , , , & show all
Pages 1807-1812 | Received 23 May 2016, Accepted 07 Jul 2016, Published online: 22 Jul 2016

References

  • GLOBOCAN. 2012. Available at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx [Last accessed 6 May 2015]
  • WHO Global Burden of Disease. 2004. Available at: http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/. [Last accessed 12 March 2015]
  • Transparency Committee opinion: vinorelbine soft capsules. 29 April 2009. Available at: http://www.has-sante.fr/portail/upload/docs/application/pdf/2009-05/navelbine_-_ct-6287.pdf. [Last accessed 12 March 2015]
  • Berkowitz N, Gupta S, Silberman G. Estimates of the lifetime direct costs of treatment for metastatic breast cancer. Value in Health 2000;3:22-30
  • Cardoso F, Costa A, Norton L, et al.; European School of Oncology; European Society of Medical Oncology. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast 2014;23:489-502
  • Gebbia V, Puozzo C. Oral versus intravenous vinorelbine: clinical safety profile. Expert Opin Drug Saf 2005;4:915-28
  • Allen JM. Economic/societal burden of metastatic breast cancer: a US perspective. Am J Manag Care 2010;16:697-704
  • Burge F, Lawson B, Johnston G. Trends in the place of death of cancer patients. CMAJ 2003;168:265-70
  • Grunfeld E, Coyle D, Whelan T, et al. Family caregiver burden: results of a longitudinal study of breast cancer patients and their principal caregivers. CMAJ 2004;170:1795-801
  • Lidgren M, Wilking N, Jönsson B, Rehnberg C. Resource use and costs associated with different states of breast cancer. Int J Technol Assess Health Care 2007;23:223-31
  • Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-15
  • Catania C, Didier F, Leon ME, et al. Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancer. Breast Canc Res Treat 2005;92:265-72
  • Jensen LH, Osterlind K, Rytter C. Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer 2008;62:85-91
  • Taylor H, Burcombe R, Hill S, et al. Assessing the impact on staff resource and patient waiting time of a switch from I.V. to oral chemotherapy: time and motion model for HTAS. Proc NCRI Cancer Conference 2005;abst. P435
  • James RD, Barni S, Fischer von Weikersthal L, et al. Improving chemotherapy capacity by switching from IV to oral vinorelbine. Eur J Oncol Pharm 2010;4:14-18
  • Delgado J, Febrer L, Nieves D, et al. Cost-reduction analysis for oral versus intravenous fludarabine (Beneflur) in Spain. Farm Hosp 2009;33:240-6
  • Lewden-Bernadac B, Courant-Menanteau M, Perrocheau G, et al. Chimiothérapie à domicile et réseau ville-hôpital: expérience du réseau Onco Pays-de-la-Loire Bulletin du Cancer 2008;95:543-9

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.